A U.S. appeals court on Wednesday dealt a major blow to Merck & Co Inc as it upheld a ruling that threw out a $2.54 billion jury verdict the drugmaker had won against Gilead Sciences Inc. The U.S. Court of Appeals for the Federal Circuit upheld a determination by a federal judge in Delaware that the Merck patent at issue in the case, which relates to hepatitis C treatment, was invalid. Merck said in a statement it was disappointed with the decision and reviewing its options for an appeal, while Gilead said it was pleased with the ruling and confident it would be upheld if appealed further.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!